Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics II

Date: Tuesday, November 7, 2017

Time: 4:30PM-6:00PM

Meeting: 2017 ACR/ARHP Annual Meeting

Abstract Number: 2884

A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis

Abstract Number: 2885

Tadalafil Reduces Skin Fibrosis and Profibrotic Genes Expression in Patients with Systemic Sclerosis

Abstract Number: 2886

Safety and Efficacy of Long-Time Intensified Rituximab Treatment in Patients with Systemic Sclerosis

Abstract Number: 2887

Long-Term Follow-up Report on Japanese Patients with Severe Systemic Sclerosis after Autologous Hematopoietic Stem Cell Transplantation

Abstract Number: 2888

Corticosteroid-Sparing Benefit of Intravenous Immunoglobulins in Systemic Sclerosis-Associated Inflammatory Myopathy: A Retrospective Study of 54 Patients

Abstract Number: 2889

Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.